According to an article written by CapsCanada, it is estimated that the U.S. relies on China and India for 75%-80% of its supply of active pharmaceutical ingredients (APIs), excipients, finished dosage pharmaceuticals, and generic drugs.

At the beginning of COVID-19, India restricted export of many common medicines and pharmaceutical ingredients. Moreover, political tension could provoke China and India to close borders and essentially cause U.S. drug supplies to evaporate. A white paper, written by the company, calls for deglobalization of API production. It suggests that the U.S. can provide incentives to move pharmaceutical manufacturing back to the Western Hemisphere (U.S., Canada, Latin America) to diversify the supply chain and increase transparency of API and raw ingredient sources.

U.S. launches project to promote pharma manufacturing
The U.S. Department of Health and Human Services on May 19 announced a new project to promote U.S.-based pharmaceutical manufacturing to secure the supply...

COVID-19: A double-edged sword for the pharma industry
The COVID-19 pandemic is causing major disruptions to pharmaceutical R&D activities, despite the pressing need for treatments and diagnostics for the...